Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks

Abstract

SummaryBackgroundObesity has reached epidemic proportions, with >40% of the US population affected. Although traditionally managed by lifestyle modification, and less frequently by bariatric therapies, there are significant pharmacological advancements.AimsTo conduct a narrative review of the neurohormonal and physiological understanding of weight gain and obesity, and the development, clinical testing, indications, expected clinical outcomes, and associated risks of current FDA‐approved and upcoming anti‐obesity medications (AOMs).MethodsWe conducted a comprehensive review in PubMed for articles on pathophysiology and complications of obesity, including terms ‘neurohormonal’, ‘obesity’, ‘incretin’, and ‘weight loss’. Next, we searched for clinical trial data of all FDA‐approved AOMs, including both the generic and trade names of orlistat, phentermine/topiramate, bupropion/naltrexone, liraglutide, and semaglutide. Additional searches were conducted for tirzepatide and retatrutide ‐ medications expecting regulatory approval. Searches included combinations of terms related to mechanism of action, indications, side effects, risks, and future directions.ResultsWe reviewed the pathophysiology of obesity, including specific role of incretins and glucagon. Clinical data supporting the use of various FDA‐approved medications for weight loss are presented, including placebo‐controlled or, when available, head‐to‐head trials. Beneficial metabolic effects, including impact on liver disease, adverse effects and risks of medications are discussed, including altered gastrointestinal motility and risk for periprocedural aspiration.ConclusionAOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks. Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice for combating obesity and its metabolic consequences such as metabolic dysfunction‐associated steatotic liver disease.

Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists

“…GLP1R agonists can induce a decrease in body weight [146]. This effect is positive in patients with overweight or obesity.…”

Advances in Drug Treatments for Companion Animal Obesity

“…In contrast, several obesity drugs are available for human use, and a promising new generation of drugs has recently been approved by the FDA and adopted widely [27]. Why are these drugs already available to humans but these or similar drugs are not used in companion animals?…”

Development of Novel N-Acylhydrazone Derivatives with High Anti-obesity Activity and Improved Safety by Exploring the Pharmaceutical Properties of Aldehyde Group

“…Current therapeutic interventions for obesity face significant challenges, as behavioral therapies focused on reducing caloric intake and increasing physical activity are frequently ineffective, , and there are limited pharmacological options available. To date, the FDA has approved only six drugs for chronic obesity management, each with its own set of limitations . For instance, bupropion is associated with adverse effects such as tachycardia, hypertension, and headache .…”

“…To date, the FDA has approved only six drugs for chronic obesity management, each with its own set of limitations. 14 For instance, bupropion is associated with adverse effects such as tachycardia, hypertension, and headache. 15 Phentermine is effective for weight loss but can lead to dyspnea, xerostomia, and increased heart rate.…”